Our Polypharmacy State: Understanding Drug-Drug Interactions (DDIs) in the Drug Development Process

In 2018 the FDA and several other regulatory bodies are expected to enact and enforce more laws related to the requirements for nonclinical drug-drug interaction (DDI) studies prior to an IND. A key component of developing a drug for market-use is to test for how it might interact with other drugs or substances in the body.

Here’s an overview of what a DDI is and how it effects the drug development process.

Continue reading